BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nelson SM, Nguyen TM, McDonald JW, MacDonald JK. Natalizumab for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2018;8:CD006097. [PMID: 30068022 DOI: 10.1002/14651858.CD006097.pub3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Chen W, Chen H, Fu S, Lin X, Zheng Z, Zhang J. Microbiome characterization and re-design by biologic agents for inflammatory bowel disease insights. Bioprocess Biosyst Eng 2021;44:929-39. [PMID: 32458051 DOI: 10.1007/s00449-020-02380-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
2 Kasikis S, Etra A, Levine JE. Current and Emerging Targeted Therapies for Acute Graft-Versus-Host Disease. BioDrugs 2021;35:19-33. [PMID: 33201499 DOI: 10.1007/s40259-020-00454-7] [Reference Citation Analysis]
3 Schreiner P, Neurath MF, Ng SC, El-Omar EM, Sharara AI, Kobayashi T, Hisamatsu T, Hibi T, Rogler G. Mechanism-Based Treatment Strategies for IBD: Cytokines, Cell Adhesion Molecules, JAK Inhibitors, Gut Flora, and More. Inflamm Intest Dis 2019;4:79-96. [PMID: 31559260 DOI: 10.1159/000500721] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 7.7] [Reference Citation Analysis]
4 Zittan E, Gralnek IM, Berns MS. The New Proactive Approach and Precision Medicine in Crohn's Disease. Biomedicines 2020;8:E193. [PMID: 32635316 DOI: 10.3390/biomedicines8070193] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
5 Ben Ghezala I, Charkaoui M, Michiels C, Bardou M, Luu M. Small Molecule Drugs in Inflammatory Bowel Diseases. Pharmaceuticals (Basel) 2021;14:637. [PMID: 34209234 DOI: 10.3390/ph14070637] [Reference Citation Analysis]
6 Jalkh G, Abi Nahed R, Macaron G, Rensel M. Safety of Newer Disease Modifying Therapies in Multiple Sclerosis. Vaccines (Basel) 2020;9:12. [PMID: 33375365 DOI: 10.3390/vaccines9010012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
7 Franzin M, Stefančič K, Lucafò M, Decorti G, Stocco G. Microbiota and Drug Response in Inflammatory Bowel Disease. Pathogens 2021;10:211. [PMID: 33669168 DOI: 10.3390/pathogens10020211] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
8 Bednarczyk M, Stege H, Grabbe S, Bros M. β2 Integrins-Multi-Functional Leukocyte Receptors in Health and Disease. Int J Mol Sci 2020;21:E1402. [PMID: 32092981 DOI: 10.3390/ijms21041402] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 12.0] [Reference Citation Analysis]
9 Singh RS, Singh A, Batra G, Kaur H, Medhi B. Novel targets for drug discovery in celiac disease. Indian J Pharmacol 2019;51:359-65. [PMID: 31831931 DOI: 10.4103/ijp.IJP_679_19] [Reference Citation Analysis]
10 Becker A, Abuazab M, Schwiertz A, Walter S, Faßbender KC, Fousse M, Unger MM. Short-chain fatty acids and intestinal inflammation in multiple sclerosis: modulation of female susceptibility by microbial products? Auto Immun Highlights 2021;12:7. [PMID: 33827656 DOI: 10.1186/s13317-021-00149-1] [Reference Citation Analysis]
11 Baiula M, Spampinato S, Gentilucci L, Tolomelli A. Novel Ligands Targeting α4β1 Integrin: Therapeutic Applications and Perspectives. Front Chem 2019;7:489. [PMID: 31338363 DOI: 10.3389/fchem.2019.00489] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
12 Ullrich KA, Schulze LL, Paap EM, Müller TM, Neurath MF, Zundler S. Immunology of IL-12: An update on functional activities and implications for disease. EXCLI J 2020;19:1563-89. [PMID: 33408595 DOI: 10.17179/excli2020-3104] [Cited by in F6Publishing: 2] [Reference Citation Analysis]